Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2026-07-31 20:00:16 ET · period of report 2026-07-31 · accession 0001864158-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 20:00 | 2026-07-31 | JANX | Campbell David Alan | Pres, CEO, Dir | G - Gift | $0.00 | -123.8K | 264.7K | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-31 | G | D | 123,840 | $0.00 | 264,742 | D | — | — |